View Item 

Show simple item record

Pharmacokinetics of Quinapril and its Active Metabolite Quinaprilat During Continuous Ambulatory Peritoneal Dialysis
dc.contributor.authorSwartz, R. D.en_US
dc.contributor.authorStarmann, B.en_US
dc.contributor.authorHorvath, A. M.en_US
dc.contributor.authorOlson, S. C.en_US
dc.contributor.authorPosvar, E. L.en_US
dc.date.accessioned2013-04-08T20:50:09Z
dc.date.available2013-04-08T20:50:09Z
dc.date.issued1990-12en_US
dc.identifier.citationSwartz, R. D.; Starmann, B.; Horvath, A. M.; Olson, S. C.; Posvar, E. L. (1990). "Pharmacokinetics of Quinapril and its Active Metabolite Quinaprilat During Continuous Ambulatory Peritoneal Dialysis." The Journal of Clinical Pharmacology 30(12). <http://hdl.handle.net/2027.42/97278>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97278
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titlePharmacokinetics of Quinapril and its Active Metabolite Quinaprilat During Continuous Ambulatory Peritoneal Dialysisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor Michiganen_US
dc.contributor.affiliationotherParke Davis Pharmaceutical Research Division, Warner‐Lambert Company, Ann Arbor Michigan.en_US
dc.identifier.pmid2273086en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97278/1/j.1552-4604.1990.tb01857.x.pdf
dc.identifier.doi10.1002/j.1552-4604.1990.tb01857.xen_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceBegg E, Bailey R, Lynn K, et al: The pharmacokinetics of ACE inhibitors in patients with renal impairment. J Hypertens 1989; 7: S29 – S32.en_US
dc.identifier.citedreferenceLevey A, Harrington J: Continuous peritoneal dialysis for chronic renal failure. Medicine 1982; 61: 330 – 339.en_US
dc.identifier.citedreferenceGokal R, King J, Bogle S, et al: Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4‐year analysis of a prospective multicentre study. Lancet 1987; 2: 1105 – 1109.en_US
dc.identifier.citedreferenceMaiorca R, Cancarini G, Manili L, et al: CAPD is a first class treatment: results of an eight‐year experience with a comparison of patient and method survival in CAPD and hemodialysis. Clin Nephrol 1988; 30: S3 – S7.en_US
dc.identifier.citedreferenceNolph K, Lindblad A, Novak J: Continuous ambulatory peritoneal dialysis. N Engl J Med 1988; 318: 1595 – 1600.en_US
dc.identifier.citedreferenceWolfe R, Port F, Guire K, et al: Trends in survival in hemodialysis versus CAPD patients (1980–1986). Abstract. Am Soc Nephrol 22nd Annual Meeting, December 1989.en_US
dc.identifier.citedreferenceBaum M, Powell D, Calvin S, et al: Continuous ambulatory peritoneal dialysis in children. N Engl J Med 1982; 307: 1537 – 1542.en_US
dc.identifier.citedreferenceAmair P, Khanna R, Leibel B, et al: Continuous ambulatory peritoneal dialysis in diabetics with end‐stage renal disease. N Engl J Med 1982; 306: 625 – 630.en_US
dc.identifier.citedreferenceKurtz S, Wong V, Anderson C, et al: Continuous ambulatory peritoneal dialysis: three years' experience at the Mayo Clinic. Mayo Clin Proc 1983; 58: 633 – 639.en_US
dc.identifier.citedreferenceWu G, Khanna R, Vas I, et al: Continuous ambulatory peritoneal dialysis: no longer experimental. Can Med Assoc J 1984; 130: 699 – 707.en_US
dc.identifier.citedreferenceManintveld A, Wenting G, Schalekamp M: Does captopril lower blood pressure in anephric patients Br Med J 1979; 2: 1110 – 1111.en_US
dc.identifier.citedreferencePapadimitriou M, Zamboulis C, Alexopoulos E, et al: Alarming hyperkalemia during captopril administration in patients on regular hemodialysis. Dial Transpl 1985; 14: 473 – 475.en_US
dc.identifier.citedreferenceYamamoto T, Shimuzi M, Morioka M, et al: Role of angiotensin II in the pathogenesis of hyperdypsia in chronic renal failure. JAMA 1986; 256: 604 – 608.en_US
dc.identifier.citedreferenceOldenburg B, MacDonald G, Shelley S: Controlled trial of enalapril in patients with chronic fluid overload undergoing dialysis. Br Med J 1988; 296: 1089 – 1091.en_US
dc.identifier.citedreferenceCampbell B, Shephard A, Elliot H, et al: Prolonged converting enzyme inhibition following captopril in patients with renal insufficiency. Br J Pharmacol 1982; 13: 755 – 757.en_US
dc.identifier.citedreferenceDuchin K, Pierides A, Heald A, et al: Elimination kinetics of captopril in patients with renal failure. Kid Int 1984; 25: 942 – 947.en_US
dc.identifier.citedreferenceBlum R, Kohli R, Olson S, et al: Pharmacokinetics of quinapril HCl and its active metabolite, quinaprilat, in patients with end‐stage renal disease on chronic hemodialysis (Abstract). American College of Clinical Pharmacology, 19th Annual Meeting; Las Vegas, NV; Nov 1990.en_US
dc.identifier.citedreferenceFerry J, Horvath A, Easton‐Taylor M, et al: Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron‐capture detection. J Chromatogr 1987; 421: 187 – 191.en_US
dc.identifier.citedreferenceRowland M, Tozer T: Clinical Pharmacokinetics Concepts and Applications. Lea & Febiger, Philadelphia, 1980.en_US
dc.identifier.citedreferenceOlson S, Horvath A, Michniewicz B, et al: The clinical pharmacokinetics of quinapril. Angiology 1989; 40: 351 – 359.en_US
dc.identifier.citedreferenceKaplan H, Taylor D, Olson S, Andrews L: Quinapril—a preclinical review of the pharmacology, pharmocokinetics and toxicology. Angiology 1989; 40: 335 – 350.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1552-4604.1990.tb01857.x.pdf
Size:
723.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.